Key Details
Price
$5.50Annual ROE
-220.59%Beta
0.84Events Calendar
Next earnings date:
Apr 01, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Apr 01, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sept 23, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences Third Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.
IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-58 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on September 23, 2024.
Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024
ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger
ReShape Lifesciences, Inc. (NASDAQ:RSLS ) Q1 2024 Earnings Conference Call on May 15, 2024 at 4:30 PM ET featuring Michael Miller, Paul Hickey, and Thomas Stankovich. Thank you for joining the call. Now I will hand it over to Michael Miller from Rx Communications.
ReShape Lifesciences Inc. (Nasdaq: RSLS), a leading company specializing in weight loss and metabolic health solutions, will release its financial results for the first quarter of 2024 and provide a corporate update on Wednesday, May 15, 2024, after the market closes.
ReShape Lifesciences (NASDAQ: RSLS ) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for a PMA supplement. That a PMA supplement applies to the company's Lap-Band 2.0 FLEX.
ReShape Lifesciences (NASDAQ:RSLS) saw its stock soar, up 41% to 36 cents a share in premarket, after the micro-cap firm's latest obesity treatment, Lap-Band 2.0, was approved by the US Food and Drug Administration (FDA). The FDA provided the company with a PMA supplement approval for the new generation of ReShape's Lap-Band – described as a “minimally invasive alternative to surgical stapling procedures – which features ‘FLEX' technology that the company said acts as a ‘relief valve' allowing larger pieces of food to move more easily through the narrower passage created by the band.
Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023 Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023
Reshape Lifesciences (NASDAQ: RSLS ) stock is getting a boost on Wednesday without any clear news from the medical device company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is rallying today.
FAQ
- What is the primary business of ReShape Lifesciences?
- What is the ticker symbol for ReShape Lifesciences?
- Does ReShape Lifesciences pay dividends?
- What sector is ReShape Lifesciences in?
- What industry is ReShape Lifesciences in?
- What country is ReShape Lifesciences based in?
- When did ReShape Lifesciences go public?
- Is ReShape Lifesciences in the S&P 500?
- Is ReShape Lifesciences in the NASDAQ 100?
- Is ReShape Lifesciences in the Dow Jones?
- When was ReShape Lifesciences's last earnings report?
- When does ReShape Lifesciences report earnings?
- Should I buy ReShape Lifesciences stock now?